Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

• Published in: Biomedicines Vol. 11; no. 4; p. 1081
• Main Authors: Almeida Lima, Karoline, Osawa, Isabeli Yumi Araújo, Ramalho, Maria Carolina Clares, de Souza, Izadora, Guedes, Camila Banca, Souza Filho, Cláudio Henrique Dahne de, Monteiro, Linda Karolynne Seregni, Latancia, Marcela Teatin, Rocha, Clarissa Ribeiro Reily
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Antimitotic agents; Antineoplastic agents; Antioxidants; Apoptosis; Autophagy; Brain cancer; Brain tumors; Cancer therapies; Cell cycle; Chemoresistance; Chemotherapy; Detoxification; DNA damage; DNA methylation; DNA repair; Dosage and administration; Glioblastoma; Kinases; Medical prognosis; MicroRNAs; Mutation; NRF2; Oxidative stress; Patient outcomes; Physiology; Proteins; Review; Temozolomide; Therapeutic targets; Transcription factors; United States; temozolomide; NRF2; glioblastoma

The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...